

Eventide Healthcare & Life Sciences Fund

Presentation December 31, 2016



Eventide Funds: At A Glance

- Founded in 2008
- Headquartered in Boston, MA
- Vision: to offer high performance values-based asset management to individuals, financial advisors, and institutions.
- Mutual funds:
 - Eventide Gilead Fund
 - Eventide Healthcare & Life Sciences Fund
 - Eventide Multi-Asset Income Fund
- \$1.66B in net assets under management

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Eventide Healthcare & Life Sciences Fund

A: ETAHX | C: ETCHX | I: ETIHX | N: ETNHX

FUND OBJECTIVE

Seeks to provide long-term capital appreciation

ABOUT THE FUND

A non-diversified equity mutual fund investing in the healthcare and life sciences sectors (80+%) that seeks to provide long-term capital appreciation. Concentrates investments in the drug-related industries (25+%).

BENCHMARK

S&P 500 Index

SECONDARY BENCHMARK

50% S&P 400 Healthcare Index / 50% S&P 600 Healthcare Index

MORNINGSTAR CATEGORY

Health

LIPPER CATEGORY

Health/Biotech

TOTAL ASSETS

\$310MM (Inception date: December 27, 2012)

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Investment Team



**Finny Kuruville,
MD PhD**
CIO, Lead Portfolio
Manager

ROLE

Dr. Kuruville serves as the CIO for Eventide Funds, Lead Portfolio Manager on the Eventide Gilead Fund, and Lead Portfolio Manager on the Eventide Healthcare & Life Sciences Fund.



**Agustin
Mohedas, PhD**
Research Analyst

ROLE

Dr. Mohedas is primarily responsible for evaluating and monitoring new and existing healthcare investment opportunities in the portfolios.



Colin Delaney
Director of Portfolio
Operations, Product
Specialist

ROLE

Mr. Delaney serves as Director of Portfolio Operations and is a Product Specialist for the Advisory Services team at Eventide.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Our Investment Philosophy

We believe high-quality companies where we have a differentiated view from the market and that trade at a discount to intrinsic value offer superior long-term risk-adjusted returns.


There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Why would I want to invest in a
healthcare mutual fund?

Biotech has the most non-correlation of any industry

Industry-Specific Risk

% of total




Source: Morgan Stanley Strategy Team

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Large biopharma FCF surpassed US SMID cap biotech MCAP in 2010-2011

Large Biopharma Free Cash Flow

Total, \$Billion



Source: Morgan Stanley, Thomson Reuters

Large Biopharma refers to Biopharmaceutical companies valued at greater than \$10 billion

FCF stands for Free Cash Flow and is a measure of available cash, calculated as operating cash minus capital expenditures


US SMID biotech MCAP refers to the sum total market capitalization of all US-domiciled biotechnology companies valued less than \$10 billion

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

We believe healthcare is in its infancy

Human Diseases for which Science Understands the Genetic Basis


Out of ~20,000 total known human diseases



Source: *Online Mendelian Inheritance in Man, Morbid Anatomy of the Human Genome*

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Biology is moving faster than Moore's law



Source: National Human Genome Research Institute, Nature, Technology Review

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

“I believe this is biology’s
century.”


– Matthew Herper (Forbes)



There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.


Composition

Portfolio Composition[†] % of portfolio



Equity market capitalization: \$7.24B average, \$0.81B median

Industry Allocation[‡] % of portfolio




[†] Companies valued at greater than \$10 billion are Large Cap; those at less than \$1 billion are Small Cap. Portfolio Composition is subject to change at any time. Past performance does not assure future results.

^{**} Industry Allocation is subject to change at any time. Past performance does not assure future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Return

Growth of \$10,000



Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. To obtain the most recent month-end performance information and a current prospectus please call the fund, toll free at 1-877-771-EVEN (3836). As it is not possible to invest in an index, the data shown does not reflect or compare features of an actual investment, such as its objectives, cost and expenses, liquidity, safety, guarantees or insurance, fluctuations of principal or return, or tax features.

	Healthcare & Life Sciences Fund	Healthcare Blended Index	S&P500 TR Index
1yr	-16.20%	5.50%	11.96%
3yr (annualized)	7.53%	12.50%	8.87%
Inception (annualized)	19.17%	21.21%	14.45%

[†] These charts compare the Eventide Healthcare & Life Sciences Fund to index fund performance over the previous periods shown, and since inception. Since Inception returns pertain to Class N and are annualized and assume the inception date of 27 December 2012. Performance will differ for other fund classes, based upon fees and commissions. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product.

[‡] Returns pertain to Class N.

^{**} The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index from fund inception on 27 December, 2012.

Market Risk

Market Risk**

	Std. Dev.	Beta	Alpha	R-Squared
1 Year	39.07%	3.03	-36.88%	63.56%
3 Year (Annualized)	32.29%	1.62	-2.02%	29.11%
5 Year (Annualized)	-	-	-	-
Inception (Annualized) ^{††}	29.37%	1.49	1.29%	28.02%

^{††} Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc. From inception to March 31, 2015, Fund performance statistics were calculated using daily statistical information. As of March 31, 2015, performance is derived from Zephyr StyleADVISOR, which reflects monthly statistical data. The methodology has been changed to meet industry norms to allow for ease of comparison with other providers, and does not affect the consistency of the data itself.

Summary sheets prior to March 31, 2015 used daily data.

Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETNHX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETNHX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETNHX over beta times the Index. The R-Squared (R²) of ETNHX versus the Index is a measure of how closely related the variance of ETNHX returns and the variance of the Index returns are. StyleADVISOR calculates R² by squaring the correlation of monthly returns between ETNHX and the Index over the specified period.

^{‡‡} Annualized since inception market risk details assume inception date of 1 January 2013 and not Fund's actual inception date of 27 December 2012, as only full month data is included in the market risk calculations.

Contact

For Fund platform availability inquiries or to initiate a sales agreement, please contact Harry Nelson at **hnelson@eventidefunds.com** or 877-771-3836, x53.

To speak with a sales agent of the Fund, please contact Jeffrey Cave at **jcave@eventidefunds.com** or 877-771-3836, x57.

For Fund literature or prospectus, please contact **info@eventidefunds.com**.

Important Information

Mutual Funds involve risk including the possible loss of principal.

The Funds' ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. Because of ongoing market volatility, the Funds performance may be subject to substantial short-term changes.


The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, thus subject to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products.

Important Information

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Fund's portfolio may represent 0% to 100% of the Fund's portfolio with an average duration of between two and eight years.

The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in "junk bonds." Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, MLPs, preferred stocks, convertible bonds, BDCs, and yieldcos that are covered in the Fund's prospectus and SAI. The Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.



CREATE VALUE

Eventide Asset Management, LLC | One International Place, Ste. 3510 | Boston, MA 02110 | 877-771-EVEN (3836) | EVENTIDEFUNDS.COM

Appendix

Investment Team Bios



Finny Kuruvilla, MD PhD

Chief Investment Officer, Portfolio Manager, Managing Partner

Finny Kuruvilla serves as the CIO for Eventide Funds, lead Portfolio Manager on the Eventide Gilead Fund, and Portfolio Manager on the Eventide Healthcare & Life Sciences Fund.

Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and Children's Hospital Boston and a postdoctoral scientist at MIT.

He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry.



Agustin Mohedas, PhD

Research Analyst

Agustin Mohedas serves as a Research Analyst for Eventide. He is primarily responsible for evaluating and monitoring new and existing investment opportunities in the portfolios.

Prior to joining Eventide, Dr. Mohedas was an investment analyst at RA Capital where he focused on evidence-based investing in small- and mid-cap life science equities.

Dr. Mohedas holds a BS in Biomedical Engineering from Texas A&M University and a PhD in Medical Engineering Medical Physics from the Harvard-MIT Division of Health Sciences and Technology. In his doctoral research, Agustin developed small molecule compounds to treat fibrodysplasia ossificans progressiva, a rare and devastating genetic disorder.



Colin Delaney

Director of Portfolio Operations, Product Specialist

Colin Delaney serves as Director of Portfolio Operations and is a Product Specialist for the Advisory Services team at Eventide. In his role in Portfolio Operations, Mr. Delaney works closely with the Fund's Portfolio Managers and the investment team to help implement their investment strategies. In his role as Product Specialist, Mr. Delaney acts as a link between Eventide's investment team and our client Advisors, helping them understand the portfolio's investments and strategies.

Prior to Eventide, Mr. Delaney was a Senior Vice President at Jefferies LLC, where he served as a sales trader and client relations manager. In nearly 15 years at Jefferies, he was able to participate in a broad range of investment activities giving him a deep and wide understanding of the complete investment process. Mr. Delaney has a degree in Economics from St. Lawrence University.